Kairos Pharma, Ltd. (KAPA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, Ltd., a Delaware corporation, on February 6, 2025. The report addresses Item 8.01 (Other Events) regarding the Company's participation in the 13th AACR-JCA Joint Conference held from February 1 to February 5, 2025, in Maui, Hawaii.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes
There are no material financial changes reported in this filing. The primary event is the presentation of preclinical data for the Company's lead asset, KROS101, a glutocorticoid-induced tumor necrosis factor receptor agonist.
Outlook, Commentary, and Risks
- Management Commentary: CEO Dr. John S. Yu and VP of R&D Dr. Ramachandran Murali presented preclinical data on KROS101 during a plenary session at the AACR-JCA Joint Conference.
- Event Details: The conference, titled "From Cancer Discovery Science to Therapeutic Innovation," gathered researchers from the U.S., Japan, and globally to discuss advances in cancer research.
- Legal Disclaimer: The information in this Item 8.01 and the accompanying press release (Exhibit 99.1) is furnished and not deemed "filed" under the Exchange Act. It is not incorporated by reference into other filings.
Investor Verification Checklist
- Verify the specific preclinical data points for KROS101 in the press release furnished as Exhibit 99.1.
- Confirm the timeline for any potential clinical trials or regulatory filings following this presentation.
- Review the Company's most recent 10-K or 10-Q for current financial status, as this 8-K contains no financial metrics.